Skip to main content
Top
Published in: Journal of Neurology 1/2015

01-01-2015 | Original Communication

A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation

Authors: Rita Barone, M. Carrozzi, R. Parini, R. Battini, D. Martinelli, M. Elia, M. Spada, F. Lilliu, G. Ciana, A. Burlina, V. Leuzzi, M. Leoni, L. Sturiale, G. Matthijs, J. Jaeken, M. Di Rocco, D. Garozzo, A. Fiumara

Published in: Journal of Neurology | Issue 1/2015

Login to get access

Abstract

PMM2-CDG (PMM2 gene mutations) is the most common congenital disorder of N-glycosylation. We conducted a nationwide survey to characterize the frequency, clinical features, glycosylation and genetic correlates in Italian patients with PMM2-CDG. Clinical information was obtained through a questionnaire filled in by the referral physicians including demographics, neurological and systemic features, neuroimaging data and genotype. Glycosylation analyses of serum transferrin were complemented by MALDI-Mass Spectrometry (MALDI-MS). Between 1996 and 2012, data on 37 Italian patients with PMM2-CDG were collected. All the patients with a severe phenotype were unable to walk unaided, 84 % had severe intellectual disability and 81 % microcephaly. Conversely, among 17 mildly affected patients 82 % had independent ambulation, 64 % had borderline to mild intellectual disability and 35 % microcephaly. Epilepsy and stroke-like events did not occur among patients with the mild phenotype. The rate and extent of systemic involvement were more pronounced in severely affected patients. The L32R misfolding mutation of the PMM2 gene occurred in 70 % of the patients with the mild phenotype and was associated with a less severe underglycosylation of serum Tf at MALDI-MS analyses. Despite their different disease severity, all patients had progressive (olivo)ponto-cerebellar atrophy that was the hallmark clinical feature for the diagnosis. A mild neurological phenotype of PMM2-CDG marked by preserved ambulatory ability and autonomy and associated with L32R mutation is particularly frequent in Italy. PMM2-CDG should be considered in patients with even mild developmental disability and/or unexplained progressive cerebellar atrophy.
Literature
1.
go back to reference Freeze HH, Chong JX, Bamshad MJ, Ng BG (2014) Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175PubMedCentralCrossRefPubMed Freeze HH, Chong JX, Bamshad MJ, Ng BG (2014) Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175PubMedCentralCrossRefPubMed
2.
go back to reference Marquardt T, Denecke J (2003) Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 162:359–379PubMed Marquardt T, Denecke J (2003) Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 162:359–379PubMed
3.
go back to reference Funke S, Gardeitchik T, Kouwenberg D et al (2013) Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A 161A:578–584CrossRefPubMed Funke S, Gardeitchik T, Kouwenberg D et al (2013) Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A 161A:578–584CrossRefPubMed
5.
go back to reference Barone R, Sturiale L, Garozzo D (2009) Mass spectrometry in the characterization of human genetic N-Glycosylation defects. Mass Spectrom Rev 28:517–542CrossRefPubMed Barone R, Sturiale L, Garozzo D (2009) Mass spectrometry in the characterization of human genetic N-Glycosylation defects. Mass Spectrom Rev 28:517–542CrossRefPubMed
7.
go back to reference Grünewald S (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792:827–834CrossRefPubMed Grünewald S (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792:827–834CrossRefPubMed
8.
go back to reference Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlström J, Martinsson T (2001) Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. Hum Genet 108:359–367CrossRefPubMed Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlström J, Martinsson T (2001) Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. Hum Genet 108:359–367CrossRefPubMed
9.
go back to reference Pérez-Dueñas B, García-Cazorla A, Pineda M et al (2009) Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations. Eur J Paediatr Neurol 13:444–451CrossRefPubMed Pérez-Dueñas B, García-Cazorla A, Pineda M et al (2009) Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations. Eur J Paediatr Neurol 13:444–451CrossRefPubMed
10.
go back to reference de Lonlay P, Seta N, Barrot S et al (2001) A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 38:14–19PubMedCentralCrossRefPubMed de Lonlay P, Seta N, Barrot S et al (2001) A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 38:14–19PubMedCentralCrossRefPubMed
11.
go back to reference Barone R, Fiumara A, Jaeken J (2014) Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin Neurol 34:357–366CrossRefPubMed Barone R, Fiumara A, Jaeken J (2014) Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin Neurol 34:357–366CrossRefPubMed
12.
go back to reference Sturiale L, Barone R, Palmigiano A et al (2008) Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS. Proteomics 8:3822–3832CrossRefPubMed Sturiale L, Barone R, Palmigiano A et al (2008) Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS. Proteomics 8:3822–3832CrossRefPubMed
13.
go back to reference Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J (1998) Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet 62:542–550PubMedCentralCrossRefPubMed Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J (1998) Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet 62:542–550PubMedCentralCrossRefPubMed
14.
go back to reference Pavone L, Fiumara A, Barone R et al (1996) Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I. J Neurol 243:700–705CrossRefPubMed Pavone L, Fiumara A, Barone R et al (1996) Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I. J Neurol 243:700–705CrossRefPubMed
15.
go back to reference Veneselli E, Biancheri R, Di Rocco M, Tortorelli S (1998) Neurophysiological findings in a case of carbohydrate-deficient glycoprotein (CDG) syndrome type I with phosphomannomutase deficiency. Eur J Paediatr Neurol 2:239–244CrossRefPubMed Veneselli E, Biancheri R, Di Rocco M, Tortorelli S (1998) Neurophysiological findings in a case of carbohydrate-deficient glycoprotein (CDG) syndrome type I with phosphomannomutase deficiency. Eur J Paediatr Neurol 2:239–244CrossRefPubMed
16.
go back to reference Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, Carrozzi M, Severini GM (2013) PMM2-CDG: phenotype and genotype in four affected family members. Gene 531:506–509CrossRefPubMed Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, Carrozzi M, Severini GM (2013) PMM2-CDG: phenotype and genotype in four affected family members. Gene 531:506–509CrossRefPubMed
17.
go back to reference Barone R, Sturiale L, Fiumara A, Uziel G, Garozzo D, Jaeken J (2007) Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). J Inherit Metab Dis 30:107CrossRefPubMed Barone R, Sturiale L, Fiumara A, Uziel G, Garozzo D, Jaeken J (2007) Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). J Inherit Metab Dis 30:107CrossRefPubMed
18.
go back to reference Di Rocco M, Barone R, Adami A et al (2000) Carbohydrate-deficient glycoprotein syndromes: the Italian experience. J Inherit Metab Dis 23:391–395CrossRefPubMed Di Rocco M, Barone R, Adami A et al (2000) Carbohydrate-deficient glycoprotein syndromes: the Italian experience. J Inherit Metab Dis 23:391–395CrossRefPubMed
19.
go back to reference Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat 30:1628–1641CrossRefPubMed Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat 30:1628–1641CrossRefPubMed
20.
go back to reference Kjaergaard S, Schwartz M, Skovby F (2001) Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child 85:236–239PubMedCentralCrossRefPubMed Kjaergaard S, Schwartz M, Skovby F (2001) Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child 85:236–239PubMedCentralCrossRefPubMed
21.
go back to reference Linssen M, Mohamed M, Wevers RA, Lefeber DJ, Morava E (2013) Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab 109:107–111CrossRefPubMed Linssen M, Mohamed M, Wevers RA, Lefeber DJ, Morava E (2013) Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab 109:107–111CrossRefPubMed
22.
go back to reference Horslen SP, Clayton PT, Harding BN, Hall NA, Keir G, Winchester B (1991) Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child 66:1027–1032PubMedCentralCrossRefPubMed Horslen SP, Clayton PT, Harding BN, Hall NA, Keir G, Winchester B (1991) Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child 66:1027–1032PubMedCentralCrossRefPubMed
23.
go back to reference Drouin-Garraud V, Belgrand M, Grünewald S et al (2001) Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling. Am J Med Genet 101:46–49CrossRefPubMed Drouin-Garraud V, Belgrand M, Grünewald S et al (2001) Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling. Am J Med Genet 101:46–49CrossRefPubMed
24.
go back to reference Aronica E, van Kempen AA, van der Heide M et al (2005) Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol 109:433–442CrossRefPubMed Aronica E, van Kempen AA, van der Heide M et al (2005) Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol 109:433–442CrossRefPubMed
25.
go back to reference Vedolin L, Gonzalez G, Souza CF, Lourenço C, Barkovich AJ (2013) Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI. Am J Neuroradiol 34:925–934CrossRefPubMed Vedolin L, Gonzalez G, Souza CF, Lourenço C, Barkovich AJ (2013) Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI. Am J Neuroradiol 34:925–934CrossRefPubMed
26.
go back to reference Sun L, Zhao Y, Zhou K, Freeze HH, Zhang YW, Xu H (2013) Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation. Mol Brain 6:52–60PubMedCentralCrossRefPubMed Sun L, Zhao Y, Zhou K, Freeze HH, Zhang YW, Xu H (2013) Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation. Mol Brain 6:52–60PubMedCentralCrossRefPubMed
27.
go back to reference Lo WY, Lagrange AH, Hernandez CC, Harrison R, Dell A, Haslam SM et al (2010) Glycosylation of b2 subunits regulates GABAA receptor biogenesis and channel gating. J Biol Chem 285:31348–31361PubMedCentralCrossRefPubMed Lo WY, Lagrange AH, Hernandez CC, Harrison R, Dell A, Haslam SM et al (2010) Glycosylation of b2 subunits regulates GABAA receptor biogenesis and channel gating. J Biol Chem 285:31348–31361PubMedCentralCrossRefPubMed
28.
go back to reference Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F et al (2000) Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386–394CrossRefPubMed Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F et al (2000) Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386–394CrossRefPubMed
29.
go back to reference Bjursell C, Erlandson A, Nordling M, Nilsson S, Wahlström J, Stibler H et al (2000) PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat 16:395–400CrossRefPubMed Bjursell C, Erlandson A, Nordling M, Nilsson S, Wahlström J, Stibler H et al (2000) PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat 16:395–400CrossRefPubMed
30.
go back to reference Pérez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L et al (2011) The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. J Inherit Metab Dis Rep 1:117–123 Pérez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L et al (2011) The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. J Inherit Metab Dis Rep 1:117–123
31.
go back to reference Westphal V, Peterson S, Patterson M et al (2001) Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet Med 3:393–398CrossRefPubMed Westphal V, Peterson S, Patterson M et al (2001) Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet Med 3:393–398CrossRefPubMed
32.
go back to reference Coman D, McGill J, MacDonald R et al (2007) Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci 14:668–672CrossRefPubMed Coman D, McGill J, MacDonald R et al (2007) Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci 14:668–672CrossRefPubMed
33.
go back to reference Vega AI, Pérez-Cerdá C, Abia D et al (2011) Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis 34:929–939CrossRefPubMed Vega AI, Pérez-Cerdá C, Abia D et al (2011) Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis 34:929–939CrossRefPubMed
34.
go back to reference Vuillaumier-Barrot S, Hetet G, Barnier A et al (2000) Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. J Med Genet 37:579–580CrossRefPubMed Vuillaumier-Barrot S, Hetet G, Barnier A et al (2000) Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. J Med Genet 37:579–580CrossRefPubMed
35.
go back to reference Mills K, Mills P, Jackson M et al (2006) Diagnosis of congenital disorders of glycosylation type-I using protein chip technology. Proteomics 6:2295–2304CrossRefPubMed Mills K, Mills P, Jackson M et al (2006) Diagnosis of congenital disorders of glycosylation type-I using protein chip technology. Proteomics 6:2295–2304CrossRefPubMed
36.
go back to reference Barone R, Sturiale V, Sofia A et al (2008) Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia. Am J Med Genet A 146A:2103–2108CrossRefPubMed Barone R, Sturiale V, Sofia A et al (2008) Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia. Am J Med Genet A 146A:2103–2108CrossRefPubMed
37.
go back to reference Hülsmeier AJ, Paesold-Burda P, Hennet T (2007) N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6:2132–2138CrossRefPubMed Hülsmeier AJ, Paesold-Burda P, Hennet T (2007) N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6:2132–2138CrossRefPubMed
Metadata
Title
A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation
Authors
Rita Barone
M. Carrozzi
R. Parini
R. Battini
D. Martinelli
M. Elia
M. Spada
F. Lilliu
G. Ciana
A. Burlina
V. Leuzzi
M. Leoni
L. Sturiale
G. Matthijs
J. Jaeken
M. Di Rocco
D. Garozzo
A. Fiumara
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 1/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7549-7

Other articles of this Issue 1/2015

Journal of Neurology 1/2015 Go to the issue